The pressured Danish pharmaceutical giant Novo Nordisk is rising almost 4 percent on the Copenhagen Stock Exchange after positive British news related to the drug Wegovy.
The country's state-run public health organization - the National Health Service - has announced that Wegovy will become an option for 1.2 million patients to prevent heart attacks and strokes. Wegovy, which has primarily been used for weight loss, will be recommended for patients who are overweight and who have previously suffered a heart attack or stroke.
However, the stock is still down just over 25 percent since the turn of the year.
